
Do you need to cleanse your body of parasites? A doctor explains the social media fad
Prescription drugsFacebookTweetLink
Follow
Lately, social media feeds have been crawling with testimonials about 'parasite cleanses' and DIY worm detoxes. Many people may be unknowingly infected, influencers on TikTok and Instagram claim, and they say they have just the cure with a mix of herbal supplements and enemas.
Kim Rogers, an influencer who calls herself the 'Worm Queen,' built a significant following by posting a video of what happened when she did a parasite cleanse that went viral on TikTok, attributing various symptoms such as brain fog and fatigue to an infection. She now sells her own remedies. Even supermodel Heidi Klum said this week that she has started a cleanse with pills that contain clove and papaya seed after viewing information about parasites and worms on Instagram.
How does one catch parasites and worms? What are the symptoms? How does one know that they have a parasitic infection? What is in these cleanses, and do they work? If they don't, how can people get rid of worms? And should people try them or not?
To help us with these questions, I spoke with CNN wellness expert Dr. Leana Wen, an emergency physician and adjunct associate professor at George Washington University. She previously served as Baltimore's health commissioner.
CNN: How does one catch parasites and worms?
Dr. Leana Wen: Let me start with a quick definition and clarification. Parasites are organisms that live on or inside a host and feed off it to survive. Many types of parasites affect human health, including external ones such as lice and ticks and internal microscopic parasites like Giardia and Cryptosporidium.
Parasitic worms are a type of internal parasite that live most frequently in the gastrointestinal tract. People typically become infected by ingesting worm eggs or larvae through contaminated food, water or soil. High-risk foods include undercooked pork or beef, raw freshwater fish, and unwashed vegetables and fruits. Not washing hands thoroughly after using the bathroom and before eating can also increase infection risk. In some cases, certain worms can penetrate the skin directly, especially in regions with inadequate sanitation and where it is the norm to walk barefoot outdoors.
In the United States and other high-income countries, such infections are uncommon. Most documented cases occur in travelers returning from regions where parasites are more common, or among people with certain exposures such as contact with infected animals. Worldwide, however, parasitic worm infections are a major global health threat. They affect an estimated 1.5 billion people — about 18% of the global population — primarily in tropical and subtropical regions, according to the World Health Organization.
CNN: What are common types of intestinal parasitic worms that infect humans? What symptoms do they cause?
Wen: Globally, the most common intestinal parasitic worm to cause human infections is a type of roundworm that causes the infection ascariasis. In the United States, it's pinworm.
Ascariasis is often asymptomatic, meaning the infected person doesn't show signs of illness. When an infestation causes symptoms, people can experience stomach pain, nausea, vomiting, diarrhea, bloody stools, loss of appetite and fever. Worm eggs can travel into the lungs and cause symptoms such as cough, blood-tinged sputum or shortness of breath.
Pinworm infection can also cause symptoms such as stomach pain, diarrhea and vomiting. Some people also have anal itching that wakes them up from sleep. Others may be asymptomatic.
A variety of other intestinal parasites can cause severe symptoms, especially if left untreated over time. These complications include malnutrition, anemia, impaired growth and development in children, and maternal and infant mortality.
CNN: How does someone know whether they have a parasitic infection? How is it diagnosed?
Wen: A common test is the fecal stool exam that looks for eggs and parasites in the stool. People are typically given specimen cups and instructions on how to collect the stool. Some parasitic infections can be detected through blood tests. Endoscopy and colonoscopy, in which a camera is passed into the gastrointestinal tract, is sometimes used with persistent symptoms and no clear diagnosis through other testing.
CNN: What is in these cleanses promoted by social media influencers and do they work?
Wen: These so-called 'cleanses' or 'detoxes' claim that they can rid the body of intestinal worms. They often contain a variety of herbs, oils and supplements that are purported to have antiparasitic properties. In many cases, people are supposed to follow a specific diet that reduces high-fat, high-sugar and ultraprocessed food.
I certainly think that a healthy diet full of vegetables, fruits, whole grains and other minimally processed food is a good idea, but such a diet doesn't get rid of parasites. Additionally, people need to know that supplements such as vitamins and herbs are not regulated like medications, so they don't have to prove that they work for the marketed purpose before they are sold. Moreover, none of these vitamins, oils, herbs and other supplements are approved by the US Food and Drug Administration as treatments for parasitic infections.
CNN: If these cleanses don't work, how can people get rid of worms?
Wen: There are a variety of antiparasitic medications approved by the FDA to treat intestinal worm infections. Some of these treatments involve a single dose, meaning all you have to do is take one pill. Others have a longer treatment course, but even then, most treatment courses are for just three days. These treatments are highly effective.
CNN: Is your advice, then, to not try these do-it-yourself cleanses?
Wen: I have three main concerns about these cleanses. First, if someone has symptoms that they think are due to parasitic infections, they need to find out if that's really the case from a health professional. Someone with fatigue, for example, may actually have a thyroid problem or low iron levels or something else totally unconnected to parasites. Abdominal symptoms can also be due to many different causes, some of which could be related to infectious organisms but many that are not. You don't want to miss another diagnosis by self-treating in this way.
Second, if what someone has is really a parasitic infection, they need proper treatment. The medications approved by the FDA are easy to use and should be targeted to the specific worm in question.
Some people may ask, well, what's the harm of trying the cleanse in someone who is asymptomatic? My third concern is that every therapy has risks. If you don't have symptoms and no reason to be using the treatment, then you have to consider that the risks may outweigh the benefits.
If people insist on trying the cleanses anyway, I recommend that they first speak with their medical provider. Because supplements are not regulated as closely as medicines, people need to be aware of exactly what they are taking.
If they are on prescription medications, they need to make sure there aren't drug interactions that can be dangerous. And, again, if there are symptoms that made them think they may have parasites, they really need an appropriate diagnosis because trying these influencer-recommended concoctions without medical guidance can lead to misdiagnosis, delayed treatment or even unintentional harm.
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
BetterRX Named to Inc. 5000 Again; Continues to Set New Standard.
SALT LAKE CITY, August 20, 2025--(BUSINESS WIRE)--Earlier this month, BetterRX was named to the 2025 Inc. 5000 list of fastest growing companies in the U.S. for the second year in a row, moving from No. 3554 to 2437. Over the past three years BetterRX has achieved an impressive 174% revenue growth as they continue to displace outdated PBMs and become the hospice pharmacy provider of choice. Because traditional PBMs were not designed for hospice workflows, they often contribute to medication delays, nurse frustration, and inflated pharmacy costs. BetterRX was built to solve these exact problems, with faster fulfillment, technology that saves nurses time, and lower medication spend. "We've built a category-defining platform that's transforming how hospice care teams work," said Ben Clarke, who served as President and then CEO during the company's rise. "I'm incredibly proud of what we've accomplished and of the team driving it forward." Over 345,000 Patients Served. 6.4 Million Prescriptions Delivered. BetterRX has now helped more than 345,000 patients receive timely, reliable medications and has processed over 6.4 million e-prescriptions nationwide. Its platform has delivered results that have set a new standard for how hospice pharmacy should be done: Nurses save 5 to 6 hours each week, allowing more time with patients Net Promoter Score of 90+, among the highest in healthcare tech Net revenue retention of 114% over the past three years "Hospice providers across the country are walking away from outdated pharmacy benefit managers and choosing BetterRX — a faster, simpler, and fully transparent platform purpose-built for hospice care," said Clarke. Scaling the Mission with BVP Forge To support its next phase of growth, BetterRX recently secured a strategic investment from BVP Forge, the growth fund of Bessemer Venture Partners. As part of this new chapter, Tim Tannert, a healthcare executive who began his career as a pharmacist and previously served as CEO of SoftWriters, has been appointed CEO. "BetterRX is a category-defining platform with clear proof of its impact on patient care and nurse efficiency," said Tannert. "Now we're scaling it. The need for better hospice pharmacy isn't going away. We're here to make sure no nurse wastes another hour and no patient waits in pain. I couldn't be more proud to work with this team on the next chapter of growth and to help more patients and families get the care they deserve." After 13 years in executive leadership, Clarke made the personal decision to step away from day-to-day operations. He will continue to support BetterRX as a board member. BVP Forge will provide strategic support through its ForgeEdge program, helping BetterRX scale operations, expand pharmacy partnerships, and deliver on its mission across the country. About BetterRX BetterRX is redefining hospice pharmacy care. As the leading hospice pharmacy platform, BetterRX combines best-in-class technology, the most reliable pharmacy fulfillment, and exceptional 24/7 clinical and customer support, setting a new standard for speed, efficiency, and trust in end-of-life care. BetterRX helps providers reduce medication costs, save critical nurse time, and deliver faster, better care to patients and families, because when it comes to hospice, every moment matters. Hospices of every size, from local agencies to national leaders, are turning to BetterRX as the trusted partner to optimize care, control costs, and transform the hospice experience for those who need it most. Visit View source version on Contacts James JarmanVP of Marketingjjarman@ 385-252-9033 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Doppsee, Park Park Zoo's eastern black rhino, in critical condition
LANSING - Despite weeks of treatment and some improvement at times, Potter Park Zoo's eastern black rhino is in critical condition, zoo officials said. Doppsee, 18, experienced "a medical emergency" on July 28. Zoo staff determined that emergency to be an obstruction, the zoo said on July 31. In an Aug. 19 statement, zoo officials said Doppsee's condition had worsened. "As many of you know, the zoo's female eastern black rhino, Doppsee, has been undergoing treatment for several weeks by a team of veterinarians led by Dr. Ronan Eustace, our Director of Animal Health," officials wrote in a statement on Facebook. "Doppsee's condition has gone up and down throughout the treatment as she seems to respond positively to treatment and then regresses. Her condition is currently critical as we continue to do everything we can to help her recover. We thank you for keeping our entire team in your thoughts as they continue to work tirelessly to treat and monitor Doppsee." The zoo had announced the illness on July 29, one day after 'her behaviors indicated a very sudden decline in her health.' Veterinarian Ronan Eustace, the zoo's director of animal health, said staff noticed signs that were "acute in nature." Doppsee stopped eating and seemed to be uncomfortable and much quieter than usual, he said. There were signs of colic, he said. Doppsee came to the Lansing zoo in 2011, Her pairing with Phineus in 2017 produced a male calf born in December 2019. The calf was named Jaali. Black rhino births in captivity are relatively rare, and Jaali, the first black rhino calf ever born at Potter Park Zoo, captured the hearts of animal fans around the world. Jaali was moved to Living Desert Zoo and Gardens in California in 2021 and paired with a female rhino from a zoo in Ohio as part of the Species Survival Plan, said Amy Morris-Hall, executive director of the Potter Park Zoological Society. The eastern black rhino is critically endangered, with an estimated 5,000 living in the wild, Morris-Hall said. There are about 57 black rhinos living at zoos, she said. This article originally appeared on Lansing State Journal: Doppsee, Park Park Zoo's eastern black rhino, in critical condition Solve the daily Crossword
Yahoo
26 minutes ago
- Yahoo
The Chemo Mouthpiece® Medical Device Significantly Reduces Oral Pain and Opioid/Analgesic Use During Chemotherapy in Multi-Center Pivotal Clinical Trial
Peer-reviewed results published in Supportive Care in Cancer, the official journal of the Multinational Association of Supportive Care in Cancer (MASCC). WILMINGTON, Del., Aug. 20, 2025 /PRNewswire/ -- Chemomouthpiece, LLC, a privately held medical device company that develops and commercializes supportive cancer care products, today announced the peer-reviewed results from its pivotal, multi-center, randomized, controlled trial were published in Supportive Care in Cancer, the official journal of the Multinational Association of Supportive Care In Cancer (MASCC). The study, "Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device", evaluated the Chemo Mouthpiece®, an FDA 510(k) cleared intraoral cryotherapy device, and demonstrated statistically significant reductions in patient-reported oral pain and opioid or analgesic use during chemotherapy treatment. Use of the Chemo Mouthpiece resulted in a 46% reduction in patient-reported oral pain symptoms compared to the control group. Additionally, there was a 68% reduction in opioid or analgesic use compared to the control group. The device showed efficacy across more than 30 chemotherapy regimens and 17 cancer types. The Chemo Mouthpiece was well-tolerated by patients, with no reported safety issues. Notably, 83% of patients indicated they would recommend the device for patients undergoing chemotherapy. A Practical Advancement in Oral Mucositis Management"Cryotherapy is a well-established strategy for mitigating oral mucositis, but its traditional delivery using ice chips presents practical challenges for patients and care teams," said Stephen Sonis, DMD, DMSc, Senior Lecturer in Oral Medicine at the Harvard School of Dental Medicine and a member of the senior faculty at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. "The data from this trial indicate that cryotherapy delivered by the Chemo Mouthpiece provided patients with an effective and well-tolerated alternative to ice that could be used throughout their treatment period, both in the clinic and at home. Chemo Mouthpiece-delivered cryotherapy reduced patients' symptoms and need to rely on analgesics for pain management." Richard Zuniga, MD, Medical Chief of Research at New York Cancer and Blood Specialists and lead study investigator, said, "The data from this rigorous, multi-center trial clearly validate the Chemo Mouthpiece as a safe and effective tool for addressing oral mucositis-related pain and related opioid use. The scope of chemotherapy regimens and cancer types included in the study underscores the potential to benefit the diverse patient population impacted by oral mucositis. These findings represent a meaningful step forward in supportive oncology care." Innovation Driven by Personal Experience The Chemo Mouthpiece device was developed by company founder and CEO David Yoskowitz, a cancer survivor who experienced firsthand the debilitating effects of oral mucositis from chemotherapy and the lack of effective, tolerable options. At the time, his treatment options included ice chips to mitigate and minimize oral pain; however, they often caused nausea, were difficult to maintain in his mouth, and failed to effectively cool the entire oral cavity. These challenges led him to engineer a better solution. "This study is not just a scientific milestone, it's deeply personal," said Yoskowitz. "It's incredibly rewarding to see the clinical data confirm the device's impact on pain reduction and patient quality of life. Not only for me, but for our original goal, to help reduce the suffering associated with oral mucositis for every at-risk patient." About the TrialThe randomized trial enrolled 164 patients undergoing chemotherapy and assigned them in a 2:1 ratio to receive either the Chemo Mouthpiece plus best supportive care (arm A) or best supportive care alone (arm B) across 16 U.S. study sites. Inclusion criteria allowed broad tumor diagnoses and chemotherapy regimens. Patients used the device during infusion and for five days post-infusion across two treatment cycles. They completed daily questionnaires to assess oral pain and analgesic use. Device tolerability was also assessed via patient surveys. Unlike traditional oral cryotherapy approaches, which are generally recommended only for chemotherapy drugs with a short half-life during infusion, the trial included regimens with both short and long half-life agents. The portability, tolerability, and user-friendly design of the Chemo Mouthpiece made it practical for patients to continue use at home, when chemotherapy agents may still be circulating in the body. This extended use was associated with improved efficacy across a variety of chemotherapy regimens. The study was published in Supportive Care in Cancer, the official journal of MASCC: Zuniga, R., Dembla, V., Alam, N. et al. Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device. Support Care Cancer 33, 732 (2025). About Oral MucositisOral mucositis is a painful and often debilitating side effect of chemotherapy, characterized by inflammation and ulceration of the mucous membranes in the mouth. It can interfere with a patient's ability to eat, drink, speak, and sleep and ultimately can reduce quality of life and delay treatment. Clinical impacts may include: Delays or dose reductions in cancer therapy Increased risk of infection due to open oral wounds Significant weight loss and nutritional challenges Greater dependence on opioids and analgesics Higher rates of ER visits and hospitalizations Increased financial and emotional burden for patients About the Chemo MouthpieceThe Chemo Mouthpiece is a self-contained cryotherapy device designed to cool the entire oral cavity during and after chemotherapy infusion. By inducing vasoconstriction in the oral cavity, the device reduces the local presence of chemotherapy drugs, helping to mitigate mucosal injury. Available by prescription only, the device is reusable, pre-filled, and designed for use in both the clinic and at home when chemotherapy may still be circulating, supporting utility across short‑ and long half‑life regimens. The FDA awarded the Chemo Mouthpiece Breakthrough Device Designation in December 2021 and the device was FDA 510(k) cleared in January 2024. INDICATION FOR USE: (Rx only) The Chemo Mouthpiece® is intended to be used to cool the oral mucosa to reduce the incidence and severity of chemotherapy induced oral mucositis in adult patients. See Important Safety Information at About Chemomouthpiece, LLCChemomouthpiece, LLC is a privately held medical device company headquartered in Wilmington, Delaware. Founded by a cancer survivor, the company's mission is to bring patient-driven innovation to the forefront of supportive oncology care. The Chemo Mouthpiece® is the company's flagship product, designed to help reduce the incidence and severity of oral mucositis, one of the most common and painful side effects of chemotherapy, impacting up to 80% of patients depending on cancer type. This release contains forward-looking statements regarding Chemomouthpiece, LLC, including its potential benefits and future development plans, which are subject to risks and uncertainties that may cause actual results to differ. The Company undertakes no obligation to update these statements except as required by law. For more information on Chemomouthpiece, LLC, please visit our website at or contact; Scott Narins, Director of Investor Relations snarins@ or Bonni Tattoli, VP, Commercial Operations at btattoli@ View original content to download multimedia: SOURCE Chemomouthpiece, LLC 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤